|
1
|
Kayser S and Levis MJ: Advances in
targeted therapy for acute myeloid leukaemia. Br J Haematol.
180:484–500. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
De Kouchkovsky I and Abdul-Hay M: ‘Acute
myeloid leukemia: A comprehensive review and 2016 update’. Blood
Cancer J. 6:e4412016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sarkadi B, Homolya L, Szakács G and Váradi
A: Human multidrug resistance ABCB and ABCG transporters:
Participation in a chemoimmunity defense system. Physiol Rev.
86:1179–1236. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Robey RW, Pluchino KM, Hall MD, Fojo AT,
Bates SE and Gottesman MM: Revisiting the role of ABC transporters
in multidrug-resistant cancer. Nat Rev Cancer. 18:452–464. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shaffer BC, Gillet JP, Patel C, Baer MR,
Bates SE and Gottesman MM: Drug resistance: Still a daunting
challenge to the successful treatment of AML. Drug Resist Updat.
15:62–69. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Steinbach D, Sell W, Voigt A, Hermann J,
Zintl F and Sauerbrey A: BCRP gene expression is associated with a
poor response to remission induction therapy in childhood acute
myeloid leukemia. Leukemia. 16:1443–1447. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yano K, Okabe C, Fujii K, Kato Y and
Ogihara T: Regulation of breast cancer resistance protein and
P-glycoprotein by ezrin, radixin and moesin in lung, intestinal and
renal cancer cell lines. J Pharm Pharmacol. 72:575–582. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR,
Liu DG, Ashby CJ Jr, Huang Y, Robey RW, Liang YJ, et al: Lapatinib
(Tykerb, GW572016) reverses multidrug resistance in cancer cells by
inhibiting the activity of ATP-binding cassette subfamily B member
1 and G member 2. Cancer Res. 68:7905–7914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Strope JD, Peer CJ, Sissung TM, Hall OM,
Huang PA, Harris EM, Gustafson KR, Henrich CJ, Sigano DM, Pauly GT,
et al: Botryllamide G is an ABCG2 inhibitor that improves lapatinib
delivery in mouse brain. Cancer Biol Ther. 21:223–230. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yeheskely-Hayon D, Regev R, Eytan GD and
Dann EJ: The tyrosine kinase inhibitors imatinib and AG957 reverse
multidrug resistance in a chronic myelogenous leukemia cell line.
Leuk Res. 29:793–802. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wilson CS, Davidson GS, Martin SB, Andries
E, Potter J, Harvey R, Ar K, Xu Y, Kopecky KJ, Ankerst DP, et al:
Gene expression profiling of adult acute myeloid leukemia
identifies novel biologic clusters for risk classification and
outcome prediction. Blood. 108:685–696. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ding XW, Wu JH and Jiang CP: ABCG2: A
potential marker of stem cells and novel target in stem cell and
cancer therapy. Life Sci. 86:631–637. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mo W and Zhang JT: Human ABCG2: Structure,
function, and its role in multidrug resistance. Int J Biochem Mol
Biol. 3:1–27. 2012.PubMed/NCBI
|
|
15
|
Yiu ZZ and Warren RB: Novel oral therapies
for psoriasis and psoriatic arthritis. Am J Clin Dermatol.
17:191–200. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rozo C, Chinenov Y, Maharaj RK, Gupta S,
Leuenberger L, Kirou KA, Bykerk VP, Goodman SM, Salmon JE and
Pernis AB: Targeting the RhoA-ROCK pathway to reverse T-cell
dysfunction in SLE. Ann Rheum Dis. 76:740–747. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Diep D, Hong K, Khun T, Zheng M, Ul-Haq A,
Jun HS, Kim YB and Chun KH: Anti-adipogenic effects of KD025
(SLx-2119), a ROCK2-specific inhibitor, in 3T3-L1 cells. Sci Rep.
8:24772018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zanin-Zhorov A, Weiss JM, Nyuydzefe MS,
Chen W, Scher JU, Mo R, Depoil D, Rao N, Liu B, Wei J, et al:
Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17
secretion in human T cells via STAT3-dependent mechanism. Proc Natl
Acad Sci USA. 111:16814–16819. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sugimoto Y, Tsukahara S, Imai Y, Sugimoto
Y, Ueda K and Tsuruo T: Reversal of breast cancer resistance
protein-mediated drug resistance by estrogen antagonists and
agonists. Mol Cancer Ther. 2:105–112. 2003.PubMed/NCBI
|
|
20
|
Imai Y, Tsukahara S, Asada S and Sugimoto
Y: Phytoestrogens/flavonoids reverse breast cancer resistance
protein/ABCG2-mediated multidrug resistance. Cancer Res.
64:4346–4352. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Luo F, Luo M, Rong QX, Zhang H, Chen Z,
Wang F, Zhao HY and Fu LW: Niclosamide, an antihelmintic drug,
enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in
Non-small cell lung cancer. J Immunother Cancer. 7:2452019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang F, Wang XK, Shi CJ, Zhang H, Hu YP,
Chen YF and Fu LW: Nilotinib enhances the efficacy of conventional
chemotherapeutic drugs in
CD34+CD38− stem cells and ABC
transporter overexpressing leukemia cells. Molecules. 19:3356–3375.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Riss TL, Moravec RA, Niles AL, Duellman S,
Benink HA, Worzella TJ and Minor L: Cell viability assays. Assay
Guidance Manual [Internet] Bethesda (MD): Eli Lilly & Company
and the National Center for Advancing Translational Sciences; May
1–2004
|
|
24
|
Percival ME, Lai C, Estey E and Hourigan
CS: Bone marrow evaluation for diagnosis and monitoring of acute
myeloid leukemia. Blood Rev. 31:185–192. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang H, Patel A, Ma SL, Li XJ, Zhang YK,
Yang PQ, Kathawala RJ, Wang YJ, Anreddy N, Fu LW and Chen ZS: In
vitro, in vivo and ex vivo characterization of ibrutinib: A potent
inhibitor of the efflux function of the transporter MRP1. Br J
Pharmacol. 171:5845–5857. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li J, Kumar P, Anreddy N, Zhang YK, Wang
YJ, Chen Y, Talele TT, Gupta K, Trombetta LD and Chen ZS:
Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance:
In vitro and in vivo studies. Oncotarget. 8:93785–93799. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang XK, To KK, Huang LY, Xu JH, Yang K,
Wang F, Huang ZC, Ye S and Fu LW: Afatinib circumvents multidrug
resistance via dually inhibiting ATP binding cassette subfamily G
member 2 in vitro and in vivo. Oncotarget. 5:11971–11985. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ejendal KF and Hrycyna CA: Multidrug
resistance and cancer: The role of the human ABC transporter ABCG2.
Curr Protein Pept Sci. 3:503–511. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shi Z, Tiwari AK, Shukla S, Robey RW, Kim
IW, Parmar S, Bates SE, Si QS, Goldblatt CS, Abraham I, et al:
Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine
kinase inhibitor AG1478. Biochem Pharmacol. 77:781–793. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang W, Sun S, Zhang W and Shi Z:
Polymorphisms of ABCG2 and its impact on clinical relevance.
Biochem Biophys Res Commun. 503:408–413. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takeshita A: Efficacy and resistance of
gemtuzumab ozogamicin for acute myeloid leukemia. Int J Hematol.
97:703–716. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tiwari AK, Sodani K, Dai CL, Ashby CJ and
Chen ZS: Revisiting the ABCs of multidrug resistance in cancer
chemotherapy. Curr Pharm Biotechnol. 12:570–594. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shi Z, Liang YJ, Chen ZS, Wang XW, Wang
XH, Ding Y, Chen LM, Yang XP and Fu LW: Reversal of
MDR1/P-glycoprotein-mediated multidrug resistance by vector-based
RNA interference in vitro and in vivo. Cancer Biol Ther. 5:39–47.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Robey RW, To KK, Polgar O, Dohse M, Fetsch
P, Dean M and Bates SE: ABCG2: A perspective. Adv Drug Deliv Rev.
61:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Szakacs G, Varadi A, Ozvegy-Laczka C and
Sarkadi B: The role of ABC transporters in drug absorption,
distribution, metabolism, excretion and toxicity (ADME-Tox). Drug
Discov Today. 13:379–393. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen L, Manautou JE, Rasmussen TP and
Zhong XB: Development of precision medicine approaches based on
inter-individual variability of BCRP/ABCG2. Acta Pharm Sin B.
9:659–674. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lou H and Dean M: Targeted therapy for
cancer stem cells: The patched pathway and ABC transporters.
Oncogene. 26:1357–1360. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Alkharabsheh O and Frankel AE: Clinical
activity and tolerability of SL-401 (Tagraxofusp): Recombinant
diphtheria toxin and interleukin-3 in hematologic malignancies.
Biomedicines. 7:62019. View Article : Google Scholar
|
|
39
|
Borin TF, Arbab AS, Gelaleti GB, Ferreira
LC, Moschetta MG, Jardim-Perassi BV, Iskander AS, Varma NR, Shankar
A, Coimbra VB, et al: Melatonin decreases breast cancer metastasis
by modulating Rho-associated kinase protein-1 expression. J Pineal
Res. 60:3–15. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rocca S, Carra G, Poggio P, Morotti A and
Brancaccio M: Targeting few to help hundreds: JAK, MAPK and ROCK
pathways as druggable targets in atypical chronic myeloid leukemia.
Mol Cancer. 17:402018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Takahashi N, Nobusue H, Shimizu T,
Sugihara E, Yamaguchi-Iwai S, Onishi N, Kunitomi H, Kuroda T and
Saya H: ROCK inhibition induces terminal adipocyte differentiation
and suppresses tumorigenesis in chemoresistant osteosarcoma cells.
Cancer Res. 79:3088–3099. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yoon JH, Nguyen TT, Duong VA, Chun KH and
Maeng HJ: Determination of KD025 (SLx-2119), a selective ROCK2
inhibitor, in rat plasma by high-performance liquid
chromatography-tandem mass spectrometry and its pharmacokinetic
application. Molecules. 25:13692020. View Article : Google Scholar
|
|
43
|
Diep D, Duong K, Choi H, Jun HS and Chun
KH: KD025 (SLx-2119) suppresses adipogenesis at intermediate stage
in human adipose-derived stem cells. Adipocyte. 8:114–124. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Flynn R, Paz K, Du J, Reichenbach DK,
Taylor PA, Panoskaltsis-Mortari A, Vulic A, Luznik L, MacDonald KK,
Hill GR, et al: Targeted Rho-associated kinase 2 inhibition
suppresses murine and human chronic GVHD through a Stat3-dependent
mechanism. Blood. 127:2144–2154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
D'Amato L, Dell'Aversana C, Conte M,
Ciotta A, Scisciola L, Carissimo A, Nebbioso A and Altucci L:
ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent
pathways in acute myeloid leukemias. Epigenetics. 10:6–18. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang XK, He JH, Xu JH, Ye S, Wang F, Zhang
H, Huang ZC, To KK and Fu LW: Afatinib enhances the efficacy of
conventional chemotherapeutic agents by eradicating cancer
stem-like cells. Cancer Res. 74:4431–4445. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nakamura Y, Oka M, Soda H, Shiozawa K,
Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki
T, et al: Gefitinib (‘Iressa’, ZD1839), an epidermal growth factor
receptor tyrosine kinase inhibitor, reverses breast cancer
resistance protein/ABCG2-mediated drug resistance. Cancer Res.
65:1541–1546. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lee JY, Stevens RP, Kash M, Zhou C,
Koloteva A, Renema P, Paudel SS and Stevens T: KD025 shifts
pulmonary endothelial cell bioenergetics and decreases baseline
lung permeability. Am J Respir Cell Mol Biol. Jul 6–2020.(Epub
ahead of print). View Article : Google Scholar
|
